Johnson & Johnson reported better-than-expected Q2 2026 results with adjusted EPS of $2.90, surpassing estimates, and revenue of $25.31 billion, driven by strong pharmaceutical sales. Key growth came from the Innovative Medicine segment, with notable sales from Tremfya and Darzalex offsetting patent losses on older drugs. The company raised its full-year 2026 guidance to $100.8-$101.4 billion in sales and adjusted EPS of $11.60-$11.75. CEO Joaquin Duato highlighted recent product approvals and a strong innovation pipeline, signaling confidence in reaching over $100 billion in annual revenue for the first time in its history.
Three dividend stocks—Johnson & Johnson, Realty Income, and JPMorgan Chase—are highlighted as strong retirement investments due to their reliable and growing payouts. Johnson & Johnson boasts a 64-year streak of dividend increases supported by accele...
PepsiCo announced that Joaquin Duato, Chairman and CEO of Johnson & Johnson, will join its Board of Directors as an independent member effective December 1, 2026. Duato will serve on the Audit Committee, bringing over three decades of leadership expe...
